Mark Chin
Insider Reports History
- Location
- London, United Kingdom
- Signature
- By: /s/ Rahul Khara, as Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Mark Chin:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| IMARA Inc. | Director | Common Stock | 2,344,072 | $35,477,530 | $15.14 | 02 Jun 2022 | By entities affiliated with Arix Bioscience plc |
| Iterum Therapeutics plc | Director | Ordinary Shares | 18,306 | $25,628 | $1.40 | 15 Jun 2023 | Direct |
| Harpoon Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $23.00 | 11 Mar 2024 | Direct |
| Disc Medicine, Inc. | Director | Stock Option (Right to Buy) | 10,000 | 11 Jun 2025 | Direct | ||
| IMARA Inc. | Director | Stock Options (Right to Buy) | 8,500 | 02 Jun 2022 | Direct | ||
| Harpoon Therapeutics, Inc. | Director | Director Stock Option (Right to Buy) | 0 | 11 Mar 2024 | Direct | ||
| Iterum Therapeutics plc | Director | Restricted Share Units | 0 | 15 Jun 2023 | Direct | ||
| Pyxis Oncology, Inc. | Former Director | Common Stock | 0 | $1.40 | 21 Apr 2022 | Indirect |